Related Experiment Video
Updated: Jul 6, 2025
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a
Husam Abu Suilik1, Fouad Jaber2, Mohamed Abuelazm3
1Faculty of Medicine, Hashemite University, Zarqa, Jordan.
Background And Objective:
One sphingosine-1-phosphate (S1P) receptor modulator is approved (ozanimod) and another (etrasimod) is under investigation for the induction and maintenance of remission of ulcerative colitis (UC). We aim to evaluate the efficacy and safety of S1P modulators in patients with active UC.
Methods:
We conducted a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs), which were retrieved by systematically searching: PubMed, Web of Science, SCOPUS, and Cochrane through May 13th, 2023. We used the fixed-effect model to pool dichotomous data using risk ratio (RR) with a 95% confidence interval (CI).
Results:
Five RCTs with a total of 1990 patients were included. S1P receptor modulators were significantly associated with increased clinical response during both the induction (RR 1.71 with 95% CI [1.50, 1.94], P = 0.00001) and maintenance phases (RR 1.89 with 95% CI [1.33, 2.69], P = 0.0004); clinical remission rates during both induction (RR 2.76 with 95% CI [1.88, 4.05], P = 0.00001) and maintenance phases (RR 3.34 with 95% CI [1.41, 7.94], P = 0.006); endoscopic improvement during both induction (RR 2.15 with 95% CI [1.71, 2.70], P = 0.00001) and maintenance phases (RR 2.41 with 95% CI [1.15, 5.05], P = 0.02); and histologic remission during both induction (RR 2.60 with 95% CI [1.89, 3.57] [1.17, 2.10], P = 0.00001) and maintenance phases (RR 2.52 with 95% CI [1.89, 3.37], P = 0.00001). Finally, there was no difference regarding safety outcomes as compared to placebo in both the induction and maintenance phases.
Conclusion:
S1P receptor modulators are effective in inducing and maintaining remission in patients with moderate to severe UC.
Insights
Sphingosine-1-phosphate (S1P) receptor modulators effectively induce and maintain remission in ulcerative colitis (UC) patients. These treatments show significant efficacy in clinical response, remission, and endoscopic and histologic improvement with no increased safety concerns compared to placebo.
Area of Science:
- Gastroenterology and immunology
- Pharmacology and drug development
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Sphingosine-1-phosphate (S1P) receptor modulators, including ozanimod and etrasimod, are emerging therapies for UC.
Approach:
- A systematic review and meta-analysis of five randomized controlled trials (RCTs) involving 1990 patients with active UC.
- Data were pooled using a fixed-effect model to calculate risk ratios (RR) and 95% confidence intervals (CI).
Key Points:
- S1P receptor modulators significantly increased clinical response (RR 1.71 induction, 1.89 maintenance) and remission rates (RR 2.76 induction, 3.34 maintenance).
- Endoscopic improvement (RR 2.15 induction, 2.41 maintenance) and histologic remission (RR 2.60 induction, 2.52 maintenance) were also significantly enhanced.
- No significant differences in safety outcomes were observed between S1P modulators and placebo in either induction or maintenance phases.
Conclusions:
- S1P receptor modulators are a safe and effective therapeutic option for inducing and maintaining remission in patients with moderate to severe ulcerative colitis.
- These findings support the use of S1P modulators in clinical practice for managing UC.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...